Coupons.Com Inc (NYSE: COUP) is the most recent small cap digital coupon or daily deal stock to emerge in a spectacular IPO to challenge existing players like mid cap Groupon Inc (NASDAQ: GRPN) and small caps LiveDeal Inc (NASDAQ: LIVE) and RetailMeNot Inc (NASDAQ: SALE). However and since the recent IPO, small cap Coupons.Com has been a relatively flat deal for investors.
What is Coupons.Com Inc?Small cap Coupons.Com calls itself a leader in digital coupons that�operates a promotion platform that connects brands and retailers with consumers through Web, mobile and social channels. Over 2,000 brands from more than 700 consumer packaged goods companies and many grocery, drug and mass merchandise retailers use Coupons.Com�� platform to deliver digital coupons to consumers, including printable coupons, save-to-card coupon and coupon�codes for e-commerce.�Coupons.Com also sells advertising for�its online and mobile properties and has built�out a�large network of retailers and publishers spanning more than �58,000 store locations in North America and approximately 30,000 third-party websites. The Coupons.com�� site itself�receives more than 17 million unique visitors a month on average.
Top 10 India Stocks To Watch Right Now: Weatherford International Ltd(WFT)
Weatherford International Ltd. provides equipment and services used in the drilling, evaluation, completion, production, and intervention of oil and natural gas wells worldwide. It offers artificial lift systems, which include reciprocating rod lift systems, progressing cavity pumps, gas lift systems, hydraulic lift systems, plunger lift systems, hybrid lift systems, wellhead systems, and multiphase metering systems. The company also provides drilling services, including directional drilling, ?Secure Drilling? services, well testing, drilling-with-casing and drilling-with-liner systems, and surface logging systems; and well construction services, such as tubular running services, cementing products, liner systems, swellable products, solid tubular expandable technologies, and inflatable products and accessories. In addition, it designs and manufactures drilling jars, underreamers, rotating control devices, and other pressure-control equipment used in drilling oil and nat ural gas wells; and offers a selection of in-house or third-party manufactured equipment for the drilling, completion, and work over of oil and natural gas wells for operators and drilling contractors, as well as a line of completion tools and sand screens. Further, the company provides wireline and evaluation services; and re-entry, fishing, and thru-tubing services, as well as well abandonment and wellbore cleaning services; stimulation and chemicals, including fracturing and coiled tubing technologies, cement services, chemical systems, and drilling fluids; integrated drilling services; and pipeline and specialty services. It serves independent oil and natural gas producing companies. The company was founded in 1972 and is headquartered in Geneva, Switzerland.
Advisors' Opinion:- [By Holly LaFon]
Weatherford International Ltd. (0.4%) (WFT)(WFT - $17.36 - NYSE), based in Houston, Texas, finally resolved its tax accounting problems and various government investigations, which had been on-going for several years. It is now focused on growing its core businesses, enhancing profitability, reducing leverage and improving capital efficiency. The company is targeting total segment operating profit margin to reach 20% by 2016 from 11.3% in 2013 and reducing debt to capitalization from 52% to 25%. It aims to realize $500 million in annualized cost savings and sell four non-core businesses. Also, Weatherford plans to spin-off a portion of its international drilling rig business by the end of 2014 or early 2015. All available free cash flow generated and proceeds from asset sales will be used to reduce debt.From Mario Gabelli (Trades, Portfolio)'s Value 25 Fund first quarter 2014 shareholder commentary. Also check out: Mario Gabelli Undervalued Stocks Mario Gabelli Top Growth Companies Mario Gabelli High Yield stocks, and Stocks that Mario Gabelli keeps buying Currently 0.00/512345
Rating: 0.0/5 (0 votes)
- [By Canadian Value]
- Weatherford International (WFT) which is a services company and a direct beneficiary of the boom in horizontal drilling and fracturing in the U.S.
Top 5 Mid Cap Stocks To Watch For 2014: Intergrative Stem Cell Holdings Inc (YFRM)
Intergrative Stem Cell Holdings Inc., formerly YaFarm Technologies, Inc., incorporated on June 16, 2006, is a Web development and Web hosting company. The Company, through its wholly owned subsidiary, YaFarm Group, LLC, offers a range of business-class Website development and Web hosting products and services for small and medium-sized businesses. The Company offers Web solutions for small- and medium- sized companies, including Web development, Web hosting, Web maintenance and business image consulting services.
The Company offers Web solution packages to small and medium-sized businesses, which includes Bronze Small Business Package, Silver Medium-Sized Business Package and Gold E-Commerce Package. The Company did not generate any revenues.
Advisors' Opinion:- [By Peter Graham]
What�� the Catch With Caribbean International Holdings? According to various disclosures, transactions of $1.5k, $2k, $3k, $3.5k, $4k, $7k, $15k and $16k have or will occur to mention Caribbean International Holdings in various investment newsletters. At the beginning of last week, Caribbean International Holdings announced that it was in the final stages of construction of a new Winghouse and Entertainment Center facility on the strip in Sosua, Dominican Republic, that feature its signature wings complemented by a variety of sauce and spice choices plus a mechanical bull. Caribbean International Holdings also recently announced it will offer Winghouse restaurant franchises (for 25,000 dollars plus a percentage of gross revenues) throughout the Caribbean as well as Central and South America. Winghouse restaurants offer 18 flavor choices with four varieties of spicy heat in a country setting with mechanical bulls as the centerpiece. Finally and last May, Caribbean International Holdings announced that ��fter three months of silence,��the merger documents between YaFarm Technologies, Inc (OTCMKTS: YFRM) and the Integrated Stem Cell Institute in Cancun, Mexico, have been signed and that CIHN now has a 12.5% stake in a company that�� been a favorite of stock promoters. However, the most updated financials that I see for Caribbean International Holdings date from June of last year on Yahoo! Finance ��and A LOT can happen within a year��
Top 5 Mid Cap Stocks To Watch For 2014: Trans Global Group Inc (TGGI)
Trans Global Group Inc. are engaged in direct dial international long-distance service from the United States for commercial customers through two switches owned and operated in Kansas and Las Vegas. Advisors' Opinion:- [By Peter Graham]
Small cap green stocks Hybrid Coating Technologies, Inc (OTCBB: HCTI), Pan Global Corp (OTCMKTS: PGLO) and Trans Global Group Inc (OTCMKTS: TGGI) have been getting some attention lately in various investment newsletters or alerts with two of these stocks also being the subject of some paid promotions. But will these small cap green stocks actually deliver some green in the form of greenbacks for investors? Let�� take off the green eyeshades and take a closer look:
Top 5 Mid Cap Stocks To Watch For 2014: ChemoCentryx Inc (CCXI)
ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules, including chemokine ligands and their associated receptors, as well as related chemo-attractant receptors, all of which are known to drive inflammation. As of December 31, 2011, the Company had four drug candidates in clinical development. Its drug candidates include Traficet-EN (CCX282, GSK'786 or vercirnon), CCX140, CCX354, CCX168, CCX872, CCX507 and CCX662. The Company is also advancing several additional independent drug candidates through preclinical development. The Company�� wholly owned subsidiary is ChemoCentryx Limited.
The Company's drug candidate Traficet-EN (CCX282, GSK'786), is to control the inflammatory response underlying IBD by targeting the chemokine receptor known as CCR9. The Company has completed nine clinical trials with Traficet-EN in a total of 785 subjects, including five Phase I clinical trials (three in the United States and two in the United Kingdom), one thorough QT study in the United States (an assessment of cardiovascular safety which is required for regulatory approval), and three Phase II clinical trials (one in the Netherlands, the United Kingdom, and the United States, one in Finland and one (PROTECT-1) in Australia, Austria, Belgium, Brazil, Bulgaria, Canada, the Czech Republic, Denmark, France, Germany, Hungary, Israel, the Netherlands, Poland, South Africa, Sweden and the United Kingdom). As of December 31, 2011, the Company�� Traficet-EN drug candidate is in four pivotal Phase III clinical trials being conducted by its partner Glaxo Group Limited (GSK).
The Company's independent drug candidate CCX140, targets the chemokine receptor known as CCR2. CCX140 is a potent and selective antagonist of CCR2 that is found on subsets of monocytes and macrophages, which are cells of th! e immune system. In January 2011, the Company completed a 159-patient randomized Phase II clinical trial, conducted in Australia, the Czech Republic, Germany, Hungary and New Zealand, to assess the safety and tolerability of CCX140 in patients with type 2 diabetes. In addition, CCX140 demonstrated biological activity through a dose-dependent decrease in fasting plasma glucose.
CCX354 targets the chemokine receptor known as CCR1. Synovial fluid from the joints of rheumatoid arthritis (RA) patients contains high levels of activated CCR1 chemokine ligands. The Company completed two Phase I clinical trials in a total of 84 healthy subjects, conducted in Switzerland followed by a Phase I/II clinical trial in 24 patients with stable RA, conducted in Belgium and Romania, and a Phase II proof-of-concept clinical trial in 160 patients with moderate-to-severe RA, conducted in Belgium, the Czech Republic, Germany, Hungary, Poland, Romania and the Ukraine. GSK exercised its option to further develop and commercialize CCX354 in November 2011 and had an exclusive right to initiate a Phase II b clinical trial for CCX354 in RA.
CCX168 targets the chemo-attractant C5a receptor (C5aR), which binds to a biologically activated fragment of the complement protein known as C5. As of December 31, the Company completed a Phase I clinical trial for CCX168, conducted in Switzerland. The Company initiated a Phase II proof-of-concept clinical trial in AAV in the fourth quarter of 2011. Its CCX872 is an independent next generation CCR2 drug candidate for the treatment of metabolic diseases, its CCX507 is an independent drug candidate for the treatment of inflammatory bowel disease (IBD) and CCX662 is an independent drug candidate for the treatment of glioblastoma multiforme (GBM).
The Company competes with Abbott Laboratories, Amgen Inc, AstraZeneca plc, Biogen Idec Inc, Bayer AG, Elan Corporation plc, Glaxo Group Limited, Merck & Co Inc, Merck Serono, Takeda Pharmaceutical Co Ltd, Novartis AG! , Pfizer ! Inc, Reata Pharmaceuticals, Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb, Incyte Corp and UCB Pharma.
Advisors' Opinion:- [By CRWE]
ChemoCentryx, Inc. (Nasdaq:CCXI), reported that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the BioCentury NewsMakers in the Biotech Industry Conference on Friday, September 7, 2012, at 9:30 a.m. Eastern Time at the Millennium Broadway Hotel & Conference Center in New York, NY.
No comments:
Post a Comment